AIDX logo

20/20 BIOLABS INC

AIDXNASDAQ
🏆 #5171 by market capUS Equity
$0.42▼ $0.01 (−2.21%)
After hours · at close
🔔
Track AIDX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.2%
7d▼ 8.0%
14d▼ 21.6%
30d▼ 37.0%
ytd—
1y—
🏦Market Cap
$5M
Small Cap
📈Revenue Growth (YoY)
+16.7%
Healthy
📊Gross Margin
31.5%
Moderate
💵FCF Margin
-136.6%
Thin
⚖️P/S Ratio
2.6x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$0.41 – $0.42
52-Week Range
$0.40 – $50.00
Volume
$2.00B
Avg Volume
$2.24B
Shares Outstanding
12.3M
Next Earnings
Nov 13, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$730,571
P/E Ratio
-0.6
P/S Ratio
2.6x
EPS (TTM)
$-0.54
Dividend Yield
0.00%
Dilution (1yr)
+116.3%

Why Investors Own AIDX

  • ✓High-growth profile — revenue up +29.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 79% gross margin and 20% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AIDX logo

20/20 BIOLABS INC

AIDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2M▲ +16.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
29.6%▲ +43.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$3M▼ −41.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$1.9B▲ +73770.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
10.4M▲ +116.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$258M▼ −$258M YoY
StockOtter · stockotter.space

About 20/20 BIOLABS INC

20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Barron’s·2h ago

20/20 BIOLABS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift AIDX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

20/20 BIOLABS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.